- |||||||||| lacosamide / Generic mfg., dexamethasone / Generic mfg.
Journal: H - 28 Assessment Following Acquired Injury to the Bilingual Brain: La Importancia De Los Determinantes Sociales De La Salud. (Pubmed Central) - Oct 9, 2023 Integrating sociocultural demographic factors into the neuropsychological evaluation process supports a culturally-informed assessment approach and is imperative for practice with multilingual speakers. In this case, language concerns may have indicated premorbid weakness or right-sided/bilateral hemispheric language involvement, warranting follow-up fMRI/language mapping prior to further intervention.
- |||||||||| lacosamide / Generic mfg., riluzole / Generic mfg.
Journal: Dual-pocket inhibition of Na channels by the antiepileptic drug lamotrigine. (Pubmed Central) - Oct 6, 2023 In this case, language concerns may have indicated premorbid weakness or right-sided/bilateral hemispheric language involvement, warranting follow-up fMRI/language mapping prior to further intervention. In this study, we present cryogenic electron microscopy (cryo-EM) structures of human Na1.7 bound to two clinical drugs, riluzole (RLZ) and lamotrigine (LTG), at resolutions of 2.9
- |||||||||| lacosamide / Generic mfg.
Journal: Case 321. (Pubmed Central) - Sep 26, 2023 The patient was subsequently started on lacosamide...There was no history of travel, recent infection, or vaccine administration. MRI of the brain with spectroscopy was performed for further evaluation (Figs 1-6).
- |||||||||| lacosamide / Generic mfg., propranolol / Generic mfg.
Trial completion: Lacosamide Versus Propranolol in Migraine (clinicaltrials.gov) - Sep 21, 2023 P3, N=600, Completed, Phase classification: P2/3 --> P2 Recruiting --> Completed
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma
Retrospective data, Journal, Monotherapy: Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior. (Pubmed Central) - Sep 11, 2023 Though the incidence of irritability with PER monotherapy may be higher than that with LCM monotherapy soon after medication initiation, this side effect appears to resolve spontaneously within a few months. At present, this study was the first research about PER and LCM monotherapy in pediatric patients with newly diagnosed focal epilepsy evaluating efficacy, tolerability, and behavior in China.
- |||||||||| Diacomit (stiripentol) / Biocodex, Meiji Seika
Biomarker, Journal: A real-life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy. (Pubmed Central) - Sep 7, 2023 ABCB1 polymorphisms related to drug-resistance (3435 CC) or drug-sensitive phenotype (CT or TT) were found in 6 out of 7 patients. Pharmacogenomic testing on saliva proved easy and safe in clinical practice to convey information for the management of epileptic patients, especially those resistant to treatment or sensitive to severe ADRs.
- |||||||||| Spectogram Analysis: More Than Just a Rainbow (Exhibit Hall) - Aug 23, 2023 - Abstract #ASA2023ASA_5286;
Under neuromuscular blockade, the detection of seizures can be challenging. The use of bilateral BIS with spectrogram facilitates the interpretation of EEG waves, enables an early diagnosis and treatment of seizures.
- |||||||||| Propofol Induced Myoclonus (South: Hall F) - Aug 23, 2023 - Abstract #ASA2023ASA_5145;
Post-procedure he remained intubated on propofol.Overnight he had multiple episodes of generalized shaking, was started on levetiracetem, fosphenytoin, lacosamide and midazolam infusion...Midazolam and propofol were discontinued. Clonus improved with diazepam.Propofol-induced myoclonus should be considered for patients experiencing seizure-like activity who received propofol.
- |||||||||| Epidiolex (cannabidiol) / Jazz, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Bridion (sugammadex) / Merck (MSD)
Status Epilepticus Following Deep Brain Stimulator Placement in a Pediatric Patient (Exhibit Hall) - Aug 23, 2023 - Abstract #ASA2023ASA_4708; A 16 y.o. female with treatment-resistant, mixed epilepsy (managed with a VNS, lacosamide, cenobamate, Epidiolex, and zonisamide) underwent deep brain stimulator implant for high daily seizure burden...She was given Sugammadex as NMB reversal, vital signs remained stable with normal blood glucose and ABG...She remained minimally responsive, with brainstem reflexes intact. EEG showed evidence of status epilepticus, which was refractory to medical management, and she was ultimately admitted to PICU.
- |||||||||| Post-Operative Seizure: Failure to Avoid Complication in a High Risk Epilepsy Patient (Exhibit Hall) - Aug 23, 2023 - Abstract #ASA2023ASA_4113;
Two minutes after extubation, she began having tonic movements in left upper extremity and left lateral neck deviation, which rapidly progressed to tonic-clonic seizures that did not respond to midazolam, lorazepam, levetiracetam, and lacosamide. She was re-intubated and transferred to the ICU in status epilepticus.
- |||||||||| lacosamide / Generic mfg., propranolol / Generic mfg.
Enrollment open: Lacosamide Versus Propranolol in Migraine (clinicaltrials.gov) - Aug 22, 2023 P3, N=600, Recruiting, She was re-intubated and transferred to the ICU in status epilepticus. Completed --> Recruiting
- |||||||||| lacosamide / Generic mfg., propranolol / Generic mfg.
Trial completion, Enrollment change, Trial initiation date: Lacosamide Versus Propranolol in Migraine (clinicaltrials.gov) - Aug 16, 2023 P3, N=700, Completed, Perampanel and LCM had no advantages in terms of efficacy and safety among the five drugs. Recruiting --> Completed | N=300 --> 700 | Initiation date: Jul 2022 --> Jan 2022
- |||||||||| lacosamide / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients (clinicaltrials.gov) - Aug 14, 2023 P3, N=200, Recruiting, Recruiting --> Completed | N=300 --> 700 | Initiation date: Jul 2022 --> Jan 2022 N=50 --> 200 | Trial completion date: May 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023
- |||||||||| lacosamide / Generic mfg.
Retrospective data, Journal: Efficacy and tolerability of immediate switch from sodium channel blockers to Lacosamide. (Pubmed Central) - Aug 7, 2023 Seizure frequency did not change in three patients in the focal-onset group. Immediate switch to LCM showed favorable outcomes with a significant reduction in seizure frequency, high retention rates, and tolerable adverse effect profiles in both focal-onset and generalized-onset seizures.
- |||||||||| lacosamide / Generic mfg., ursodeoxycholic acid / Generic mfg.
Temozalmide-Induced Vanishing Bile Duct Syndrome (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1480; Treatment of biliary ductopenia includes supportive care, removal of the offending agent, ursodeoxycholic acid, and immunosuppression (2). Given pathology consistent with temozolomide induced liver injury and improvement with ursodiol, we concluded temozolomide was the likely the culprit for liver injury, rather than valproic acid, which though a more common culprit for DILI than temozolomide, did not fit this patient
- |||||||||| lacosamide / Generic mfg.
Journal: Therapeutic drug monitoring of lacosamide among children: is it helpful? (Pubmed Central) - Jul 24, 2023 Based on the data that has been obtained from our study, it appears that therapeutic drug monitoring for LCM may not be necessary. Nonetheless, further research in this area is needed in the light of the relatively small sample size of the study.
- |||||||||| lacosamide / Generic mfg.
Preclinical, Journal: Lacosamide Exhibits Neuroprotective Effects in a Rat Model of Parkinson's Disease. (Pubmed Central) - Jul 14, 2023 In conclusion, our study provides evidence that lacosamide has a neuroprotective effect on the rat model of PD. Further studies are required to investigate the underlying mechanisms and evaluate the potential clinical use of lacosamide as a neuroprotective agent for PD.
- |||||||||| lacosamide / Generic mfg., levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Review, Journal: The evidence for repurposing anti-epileptic drugs to target cancer. (Pubmed Central) - Jul 7, 2023 Valproic acid, oxcarbazepine, lacosamide, lamotrigine, and levetiracetam are the drugs that showed potential beneficial outcomes against different cancers. Antiepileptic drugs might be a good option for adjuvant cancer therapy, but there is a need to investigate further their efficacy in cancer therapy clinical trials.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Ospolot (sultiam) / AOP Orphan Pharma, Diacomit (stiripentol) / Biocodex, Meiji Seika
Enrollment open, Trial completion date, Trial primary completion date: EPIPOP: Population Pharmacokinetics of Antiepileptic in Pediatrics (clinicaltrials.gov) - Jul 3, 2023 P=N/A, N=1000, Recruiting, Antiepileptic drugs might be a good option for adjuvant cancer therapy, but there is a need to investigate further their efficacy in cancer therapy clinical trials. Unknown status --> Recruiting | Trial completion date: Jun 2022 --> Jun 2026 | Trial primary completion date: Jun 2022 --> Jun 2026
- |||||||||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Journal: Synergistic effects of vagus nerve stimulation and antiseizure medication. (Pubmed Central) - Jun 27, 2023 Our data suggest that the combination of VNS with ASMs belonging to either SV2A modulators or slow sodium channel inhibitors could be optimal to achieve a better seizure control following VNS. However, these preliminary data require further validation under controlled conditions.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Review, Journal: Antiseizure Medication-Induced Alopecia: A Literature Review. (Pubmed Central) - Jun 27, 2023 Alopecia should be considered one important adverse effect of ASMs. Patients reporting hair loss with ASM therapy should be further investigated, and specialist consultation is recommended.
|